Table 2. Baseline Donor and Graft Preservation Characteristics and Recipient Characteristics.
| Characteristic | Participantsa | |
|---|---|---|
| CDA group (n = 38) | Control group (n = 36) | |
| Donor and graft preservation | ||
| Donor age, median (IQR), y | 57 (49-70) | 59 (48-68) |
| Donor type | ||
| DBD | 26 (68.4) | 23 (63.9) |
| DCD | 12 (31.5) | 13 (36.1) |
| Warm ischemia time if DCD, median (IQR), minb | ||
| All phases | 17 (16-21) | 16 (12-25) |
| Agonal phasec | 10 (6-13) | 9 (2-13) |
| ICU LOS, median (IQR), d | 3 (1-7) | 4 (3-7) |
| Donor cause of death | ||
| Trauma | 6 (15.8) | 11 (30.6) |
| CVA | 20 (52.6) | 11 (30.6) |
| Anoxia | 0 | 2 (5.6) |
| Other | 12 (31.6) | 12 (33.3) |
| Type of preservation solution | ||
| HTK | 6 (15.8) | 5 (13.9) |
| UW | 7 (18.4) | 5 (13.9) |
| IGL-1 | 25 (65.8) | 25 (69.4) |
| Other | 0 | 1 (2.8) |
| DBD duration, median (IQR), hd | 13.3 (10.5-17.1) | 14.3 (10.0-20.8) |
| Donor hepatectomy duration, median (IQR), mine | 34.5 (25.0-46.0) | 32.5 (26.0-42.5) |
| CIT, median (IQR), hf | 5.8 (4.8-8.1) | 5.8 (5.1-8.1) |
| Recipient | ||
| Age, median (IQR), y | 59 (53-66) | 60 (51-68) |
| MELD score, median (IQR)g | 13.2 (8.7-19.1) | 13.8 (10.8-19.4) |
| Indication for live transplant | ||
| Metabolic disease | 4 (10.5) | 3 (8.3) |
| HCC | 18 (47.4) | 12 (33.3) |
| Chronic liver disease | 25 (65.8) | 18 (50.0) |
| Ethyl | 23 (60.5) | 18 (50.0) |
| HBV | 2 (5.3) | 0 |
| HCV | 2 (5.3) | 0 |
| Cholestatic disease | 4 (10.5) | 4 (11.1) |
| NASH | 2 (5.3) | 10 (27.8) |
| Cryptogenic | 1 (2.6) | 0 |
| Implantation duration, median (IQR), minh | 39.5 (35.0-48.0) | 38.5 (34.5-45.0) |
| ICU LOS, median (IQR), d | 3 (1.5-6.5) | 4 (2.5-7.0) |
Abbreviations: CDA, combined drug approach; CIT, cold ischemia time; CVA, cerebrovascular accident; DBD, donation after brain death; DCD, donation after circulatory death; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HTK, histidine tryptophan ketoglutarate; ICU, intensive care unit; IGL, Institut Georges Lopez; LOS, length of stay; MELD, Model for End-stage Liver Disease; NASH, nonalcoholic steatohepatitis; UW, University of Wisconsin.
Data are presented as number (percentage) of participants unless otherwise indicated.
Time from withdrawal of life-sustaining therapy to start of cold aortic perfusion in the donor (applied only to DCD liver transplants).
Time from withdrawal of life-sustaining therapy to circulatory arrest (mean arterial pressure <30 mm Hg).
Time between the brain death diagnosis and the cold aortic perfusion.
Time between the start of aortic cold perfusion and completion of the donor hepatectomy, when the liver was placed in ice water on the back table.
Time between the start of cold aortic perfusion and removal of the liver from cold storage before implantation.
Possible score range of 4 to 40, with higher scores indicating a higher risk of mortality at 3 months.
Time required for graft reperfusion between the liver leaving the ice water and completion of portal vein anastomosis.